Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THALASSA: VAY736 in high symptom burden Sjogren's syndrome
CTR20263185Phase 3Active
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Started Aug 2026; status: active.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on CTR20263185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263185.